Compare KT & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KT | DVA |
|---|---|---|
| Founded | 1981 | 1994 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Misc Health and Biotechnology Services |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 10.1B |
| IPO Year | 2002 | 2002 |
| Metric | KT | DVA |
|---|---|---|
| Price | $21.56 | $154.44 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $156.75 |
| AVG Volume (30 Days) | ★ 1.6M | 730.0K |
| Earning Date | 02-10-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.41% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 9.84 |
| Revenue | N/A | ★ $13,643,069,000.00 |
| Revenue This Year | N/A | $3.85 |
| Revenue Next Year | $1.97 | $3.07 |
| P/E Ratio | ★ $15.73 | $15.90 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $16.25 | $101.00 |
| 52 Week High | $24.58 | $159.42 |
| Indicator | KT | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 45.18 | 59.71 |
| Support Level | $21.36 | $146.05 |
| Resistance Level | $24.58 | $158.31 |
| Average True Range (ATR) | 0.42 | 3.81 |
| MACD | -0.10 | -0.46 |
| Stochastic Oscillator | 47.29 | 75.16 |
KT is South Korea's largest fixed-line telecom operator, with around 11.5 million fixed-line broadband customers and 9.5 million IPTV customers, and is the second-largest wireless operator with 28 million subscribers. Additionally, it has a number of nontelecom businesses, including real estate, payment processing, artificial intelligence, and IDC/cloud services, many of which are the focus of its growth strategy. The company was formed from the previously government-owned, monopoly telecom business and was listed in 1998. After selling its mobile business in 1994 (forming its mobile competitor, SK Telecom), KT created its own mobile operator in 1997.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.